Advertisement
UK markets open in 3 hours 8 minutes
  • NIKKEI 225

    38,051.13
    +422.65 (+1.12%)
     
  • HANG SENG

    17,583.35
    +298.81 (+1.73%)
     
  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     
  • GOLD FUTURES

    2,345.10
    +2.60 (+0.11%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,533.55
    +31.52 (+0.06%)
     
  • CMC Crypto 200

    1,390.19
    +7.62 (+0.55%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

US STOCKS-Futures climb after three-day run

* Futures up: Dow 45 pts, S&P 4.25 pts, Nasdaq 8.5 pts

* Gilead falls as Express Scripts chooses AbbVie (Xetra: 4AB.DE - news) treatment

* Biocryst gets FDA OK for intravenous flu drug

By Chuck Mikolajczak

NEW YORK, Dec 22 (Reuters) - U.S. stock index futures advanced on Monday, after the S&P 500 notched its best weekly performance in almost two months, as oil prices continued to show signs of stabilizing.

* Brent crude hit a high of $62.97 and WTI crude rose to as much as $58.53 amid investor confidence there would be no substantial price loss in the run-up to the new year. However, Brent pulled back to last trade down 14 cents to $61.24 while U.S. crude was last off 0.4 percent at $56.91.

ADVERTISEMENT

* The benchmark S&P index rose 3.4 percent last week, boosted by a 5 percent jump over three sessions, after the U.S. Federal Reserve said it would take a "patient" approach toward raising interest rates and as oil prices appeared to stabilize. The S&P energy index surged nearly 10 percent for the week.

* Investors await existing home sales data, due out at 10:00 a.m. (1500 GMT). Expectations are for a decline of 1 percent.

* Trading volume is expected to be light this week due to the Christmas holiday, which could increase volatility. U.S. equity markets will operate a shortened session on Wednesday and be closed on Thursday.

* Gilead Sciences (NasdaqGS: GILD - news) lost 6.6 percent to $101.30 in premarket trade. Express Scripts, the nation's largest pharmacy benefit manager, has lined up a cheaper price from AbbVie Inc on its newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead's treatments.

* BioCryst Pharmaceuticals (NasdaqGS: BCRX - news) jumped 10.2 percent to $12.30 in light premarket trade after the U.S. Food and Drug Administration approved its intravenous flu drug.

* Rising energy shares lifted European equities, while Greece's bourse advanced after its prime minister offered Sunday to bring pro-European independents into the government.

* Asian shares took their cues from Wall Street's strong finish last week and moved higher, also aided by the recovery in oil prices.

Futures snapshot at 7:35 a.m.:

* S&P 500 e-minis were up 4.25 points, or 0.21 percent, with 80,495 contracts changing hands.

* Nasdaq 100 e-minis were up 8.5 points, or 0.2 percent, in volume of 14,883 contracts.

* Dow e-minis were up 45 points, or 0.25 percent, with 12,172 contracts changing hands. (Editing by Bernadette Baum)